BioPharma Dive July 29, 2024
Ayman AlAbdallah spoke with PharmaVoice about some of the inroads the sector has made toward a recovery and the traits he looks for in a startup.
After a dramatic post-pandemic downturn, a sense of stabilization has returned to biotech, and more healthcare professionals feel optimistic about the market’s recovery this year, according to a March Global Data survey.
But bruises from the recent roller coaster ride remain.
Following an influx of capital into biotech in 2021, many overvalued companies failed to deliver on key milestones, which contributed to a slump the following year. And with new macroeconomic pressures overhead, including high inflation and interest rates, investors have gotten picky.
In this new normal, what kinds of technologies and companies...
Today's Sponsors
Today's Sponsor